Personalis to Participate in Digital World CB & CDx Meeting
30 9월 2020 - 5:05AM
Business Wire
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics
for cancer, today announced the company’s participation at the
Digital World CB & CDx meeting which will be held online,
September 29-October 1, 2020.
Personalis will present “Enabling the Expansive Interrogation of
a Tumor & Its Microenvironment from a Single Sample for
Translational Research and Precision Medicine,” featuring
the Personalis universal cancer immunogenomics platform, ImmunoID
NeXT™. Kedar Hastak, PhD, will present for Personalis.
Dr. Hastak will discuss challenges facing immuno-oncology
translational and clinical researchers and review the importance of
insights into the complex and dynamic interactions between the
tumor and immune cells of the cancer microenvironment. He will
present the company’s solution to these barriers, ImmunoID NeXT™,
that consolidates multiple biomarker assays into one, providing a
multidimensional view of the tumor and its microenvironment. He
will also talk about the Personalis diagnostic initiatives, NeXT
Dx™, which supports patient management and biomarker-driven
clinical trials, and NeXT CDx™, a comprehensive companion
diagnostic platform.
About Personalis, Inc.
Personalis, Inc. is a leader in population sequencing and cancer
genomics, with a focus on data, scale, efficiency and quality.
Personalis operates one of the largest sequencing operations
globally and is currently the sole sequencing provider to the U.S.
Department of Veterans Affairs Million Veteran Program (VA MVP). In
oncology, Personalis is transforming the development of
next-generation therapies by providing more comprehensive molecular
data about each patient’s cancer and immune response. The
Personalis® ImmunoID NeXT Platform® is designed to adapt to the
complex and evolving understanding of cancer, providing its
biopharmaceutical customers with information on all of the
approximately 20,000 human genes, together with the immune system,
from a single tissue sample. The Personalis Clinical Laboratory is
GxP-aligned as well as CLIA’88-certified and CAP-accredited. For
more information, please visit www.personalis.com and follow
Personalis on Twitter (@PersonalisInc).
Forward-Looking Statements
All statements in this press release that are not historical are
“forward-looking statements” within the meaning of U.S. securities
laws, including statements relating to attributes or advantages of
the ImmunoID NeXT Platform, Personalis’ services for the VA MVP,
the company’s business opportunities, leadership or growth, or
other future events. Such forward-looking statements involve risks
and uncertainties, including those related to the COVID-19
pandemic, that could cause actual results to differ materially from
any anticipated results or expectations expressed or implied by
such statements. Factors that could materially affect actual
results can be found in Personalis’ filings with the U.S.
Securities and Exchange Commission, including the company’s most
recent reports on Forms 8-K, 10-K and 10-Q, and include those
listed under the caption “Risk Factors.” Personalis disclaims any
obligation to update such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200929006085/en/
Media Contact for Personalis: Jennifer Havlek
pr@personalis.com www.personalis.com 650-752-1300
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024